Carella 55 populations of very primitive hemopoietic cells are contained in the marrow, at least in some newly diagnosed patients. Since it seems that the normal hematopoietic reservoir declines with time, it may be desirable to mobilize and collect peripheral stem cells in order to store Ph-negative progenitors as soon after diagnosis as possible.
Clinically, this observation has been confirmed after treatment with IFN-α [3] [4] [5] [6] [7] , intensive chemotherapy [8] [9] [10] [11] , and mobilization of Ph-negative progenitor cells into the peripheral blood after intensive chemotherapy [12] [13] [14] [15] . Cytogenetic and other clonality studies suggest but do not prove that these cells are part of the original "normal" population [16] [17] [18] [19] [20] . In order to obtain such cells, in vitro and in vivo approaches have been evaluated.
IN VITRO MANIPULATIONS
The Vancouver group showed in a series of elegant experiments that Ph 1 -positive cell numbers decline when put in culture, whereas Ph-negative cells not previously identifiable emerged in those cultures and showed better survival [21] [22] [23] [24] . The basic mechanism of this behavior is still unclear; however, it is important to point out that some of the emerging Ph-negative cells show characteristics of very primitive hematopoietic cells. As a result of these findings, the Vancouver group devised a trial consisting of a 10-day culture of CML bone marrow and subsequent infusion into a conditioned patient previously selected on the basis of the ability of his bone marrow to produce an adequate number of normal long-term culture-initiating cells (LTC-ICs) in vitro. Over a five-year period, they evaluated 87 patients and selected 36 for the 10-day marrow culture, of whom 22 have been autografted. Sixteen patients remained alive up to 68 months postautograft, and five were in complete or partial cytogenetic remission [25] . This technique requires considerable care and would not be suitable for many institutions.
The Minneapolis group has shown that CD34 + cells that are also DR -are predominantly or exclusively Ph-negative; in contrast, CD34 + /DR + cells are all Ph-positive [26] . It has been recently reported that in patients in early chronic phase, CD34 + DR -cells are BCR-ABL mRNA negative in 80% of patients [26] . Large-scale selection with a high-speed fluorescence-activated cell sorter, starting from a marrow harvest of 2-2.5 liters results in 1-3 × 10 5 /kg CD34 + DR -cells [5] . The frequency of colony-forming cells (CFCs) and LTC-ICs ranged from 2.6%-8.6% and 0.187%-0.233%, respectively. Both CD34 + DR -and secondary CFCs were BCR-ABL mRNA negative. Therefore, this large-scale clinical grade selection of CD34 + DR -cells allows a highly purified autograft and represents a promising step toward further gene manipulation developments.
Other approaches are the purging of Ph-positive marrow cells with interferon [27, 28] even if the previous reports were not completely confirmed, the incubation of harvested marrow with antisense oligodeoxynucleotides directed at the BCR-ABL junctional sequences [29, 30] or the upstream sequences of MYB [31, 32] CML patients. In a study conducted jointly by the Hammersmith Hospital in London and the University of Pennsylvania in Philadelphia autologous bone marrow cells were collected from patients with CML and subjected to an in vitro purging procedure using a 24mer phosphorothioate antisense oligomer directed against codons 2-7 of the human MYB gene [32] . To date, 12 patients have been recruited to this study and four have been rendered entirely or predominantly Phnegative at the three-month post-autograft assessment. This Ph-negativity has been transient in all cases [31, 32] . In Rome, eight patients with advanced-phase CML have been treated with a 26mer phosphorothioate oligomer directed symmetrically at the BCR-ABL junction. In this study, in a similar manner to that of the MYB study, autologous stem cells were purged in vitro before subsequent return to the patient as an autograft [29] . After purging, 30%-100% of cells were Phnegative, and in two patients, complete Ph-negativity was achieved post-autograft, albeit transiently.
Another concept for in vitro purging and in vivo usage is to employ an agent that would preferentially protect normal progenitors from the effects of chemotherapy. Macrophage inflammatory protein-1α is a candidate molecule that has an inhibitory effect on normal but not CML progenitors, and it may have clinical potential as a protective agent during chemotherapy or for chemotherapeutic purging of CML autograft material [33] . Finally, another novel approach involves incubation of marrow cells with ribozymes [34] [35] [36] , catalytic RNA species that can be tailored to recognize and disrupt leukemia-specific mRNA molecules.
IN VIVO MANIPULATIONS
Our team has now treated substantial numbers of patients, some resistant to IFN-α and some previously untreated, with more or less intensive chemotherapy (idarubicin, cytosine arabinoside, and etoposide) (ICE or mini-ICE protocols), followed by administration of G-CSF [13, 37, 38] . In most cases, it was possible to collect predominantly or exclusively Ph-negative myeloid progenitor cells; there is preliminary evidence that the Ph-negative progenitor cells
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The Swedish study has adopted an alternative approach to the in vivo purging technique [39] . CML patients are subjected to therapy of increasing intensity with the aim of achieving Ph-negativity in the bone marrow. Once Ph-negativity was achieved, patients proceeded to bone marrow harvest, which, despite a period on IFN, did not present any technical difficulties. A total of 194 patients have been recruited to this study, and only 4% of the 118 patients who have received IFN-α and hydroxyurea for six months became completely Ph-negative. Larger proportions became Ph-negative following successive cycles of chemotherapy. Overall, 47 patients (18% of total) achieved Ph-negativity, and 31 of these have undergone autografting with Ph-negative bone marrow. Of these 31 patients, 15 remain completely Ph-negative 35-65 months post-transplant. Sixty-eight percent of all patients entered into the study survive at six years. A proportion of all patients entered into the study have undergone allografting, which may significantly modify the survival data.
CLINICAL RESULTS WITH AN IN VIVO TECHNIQUE EMPLOYED IN GENOA
One hundred sixty-two patients with Ph-positive CML in different phases of the disease entered our procotol (Table  1A) . Thirty-eight patients were mobilized during their blastic phase, 28 patients in accelerated phase, and 96 patients in chronic phase. Thirty-eight patients in chronic phase were in the first year of disease and had not been pretreated with IFN (group A), 58 other patients had received previous IFN therapy: 27 patients for >12 months and 31 patients for <12 months (Table 1B) /day by two-h infusion on days 1-3 (ICE protocol). All the data concerning the patients pretreated with IFN-α have been recently updated [40] ; we wish to focus here on patients in an early phase of disease and not previously pretreated with IFN. Seventeen patients received the ICE protocol, and, in the end, 21 patients were given the same drugs but for only three days (mini-ICE protocol). In all cases, G-CSF was given at 5 mg/kg from day 8 after chemotherapy. In Table 2 , we have synthetized the patient characteristics at baseline before mobilization therapy. Leukaphereses were started the day the white blood cell (WBC) count exceeded 0.8 × 10 9 /l and at least 5-10 CD34 + cells/µl appearing in the peripheral blood. The procedure was performed until the total of CD34 + cells collected was at least 2 × 10 6 /kg (Fig. 1) . All patients completed the mobilization protocol, and no patient died as a result of the procedure. Toxicity consisted mainly of modest alopecia, mild mucositis, and diarrhea in the majority of patients treated with the ICE protocol. In two patients, a grade 3 oral mucositis (WHO) and diarrhea occurred. In contrast, no patient treated with the mini-ICE protocol experienced any nonhematological toxicity. Cytogenetic analysis of collected peripheral blood (Fig. 2) . Comparison of these data with the results achieved in patients pretreated with IFN-α in late chronic phase revealed a higher rate of complete cytogenetic remission among patients mobilized early at diagnosis (Table 3) . These results were supported by the significantly greater numbers of CD34 + cells, CFU-GMs, and LTC-ICs. To date, 23 of 31 cytogenetic remitter patients on PBPCs underwent autografting (Ph 1 -negative: 18 patients; MCyR: five patients). High-dose therapy consisted of Busulfan (4 mg/kg/day × 4 days) (17 patients) or IVT (idarubicin, VP-16 and single-dose TBI) (six patients). No patient died, and all patients engrafted. After recovery, all patients were treated with low doses of interleukin 2 (2 M/U/daily for five days every nine weeks) and IFN (3 M/U/daily for eight weeks). After one week of rest, the cycle was repeated for a total of three courses. Subsequently, the patients were maintained with IFN alone. The median follow-up from autografting is 13 months (range, 2-63 months). Two patients evoluted in blastic crisis at 18 and 29 months after autografting. The other 21 patients are in hematological remission, and 12 of them also in complete (six patients) or partial (six patients) cytogenetic remission in the marrow 2-35 months after autografting.
In conclusion, premobilization chemotherapy was able to provide preferential in vivo reduction of the Ph-positive stem cell population and to synergize the effects of G-CSF to stimulate the release of primitive Ph 1 -negative hematopoietic stem cells into the blood. According to these results, a European protocol under the aegis of EBMT has been proposed with the aim of finding answers to the following questions:
Which Patients Should Enter a Prospective Randomized Controlled Trial?
Clearly, all newly untreated patients, without HLAcompatible donors could reasonably be entered into an autografting study. Our proposal is different from a recent EBMT study and an MRC/ECOG study which have adopted somewhat different approaches. In the EBMT study, all patients are first treated with IFN for three months; the patients who achieve complete hematological response during this time are excluded from the autograft trial [41] . The main problem with this study is the high number of patients achieving complete hematological remission (~40%) after three months who are excluded from the autograft trial. Conversely, the MRC/ECOG study excludes only patients who achieve a good cytogenetic response after treatment with IFN, but, in this case also, three months is too short a time to achieve a major cytogenetic remission. We think that it would be better to start a randomized protocol early-at 
When Should the PBPCs be Collected?
There is no doubt that the best collection should be free of disease and contain a high number of progenitors. The collection of these cells in patients who become Phnegative after IFN could only be applied to a very small proportion of patients; on the contrary, the idea of collecting Ph-negative or prevalently Ph-negative PBPCs in an early phase of CML after chemotherapy would be attractive. In previous studies, we demonstrated that PBPCs collected from CML patients during early recovery after chemotherapy-induced aplasia contain Ph-negative cells which are able to sustain long-term Ph-negative polyclonal hemopoiesis after autografting [42] . In these studies, a high variability in the content of LTC-ICs was observed from patient to patient and among different collections. We have also found that LTC-ICs are more likely to be present in the Ph-negative collections [43] . Cytogenetic analysis of colonies derived from LTC-ICs showed there to be normal diploid elements. In patients with a long interval between diagnosis and mobilization, we could detect LTC-ICs in Ph-negative collections as well as in the absence of committed progenitor cell growth. Moreover, this suggests that this mobilizing protocol is able to produce an overshoot of probably quiescent (G 0 ) normal cells. In order to quantify the normal hemopoietic reservoir in CML patients and to assess whether the duration of the disease reduces the normal hemopoietic stem cell pool, we compared the cumulative content of mononuclear cells, CD34 + , CFU-GMs, and LTC-ICs of Ph 1 -negative blood from patients not pretreated with IFN-α who were mobilized in the first few weeks after diagnosis versus those pretreated with IFN-α one year or later after diagnosis. Moreover, we compared these data with those obtained when peripheral blood was collected from normal donors after five days of G-CSF. There was a significant difference between harvests in patients mobilized at diagnosis versus patients receiving IFN-α for >one year (Table 1B) ; therefore, the possibility of collecting a high number of Ph-negative progenitors decreases during the course of the disease [38] .
CONCLUSIONS
Residual normal hematopoiesis is present at diagnosis in some patients. During their chronic phase, the leukemic cells can be destroyed with relative ease by therapy. Various markers exist whereby leukemia cells can readily be recognized and quantitated and may thus be exploited for therapeutic purposes. Recently, we confirmed that it was possible in some cases to mobilize "diploid" PBPCs in other hematological diseases with cytogenetic markers such as Ph-positive acute lymphoblastic leukemia and myelodysplastic syndromes [44, 45] . Thus, it is likely that attention in upcoming years will focus on this aspect, giving more impact to the role of autografting. From a therapeutic point of view, there seems to be general agreement that a patient less than 55 years with an HLA-identical sibling should receive an allograft. This procedure should also be offered to younger patients who are able to find a volunteer unrelated donor (VUD). Since it has been clearly demonstrated that the normal hematopoiesis reservoir declines with time, it may be desirable to mobilize and collect PBPCs in order to store Ph-negative or prevalently Ph-negative blood as soon after diagnosis as possible when the WBC count is being controlled by hydroxyurea while the search for a VUD proceeds. After six to eight months, if a donor is not found, the patient could undergo autografting with the previously stored Ph-negative progenitors followed by IFN-α therapy. In Figure 3 , we have synthetized a therapeutic algorithm for newly diagnosed patients with CML. 
